HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 06, June 2017 – Advocacies in Support of Rare Disease Patients       » Bayer and NUS Enterprise Announce Winners of Grants4Apps? Singapore Open Innovation Challenge       » Cancer Control Efforts in Vietnam: Interview with Dr Tran Thanh Huong       » China Sets up National Lab Developing Brain-Like AI Technology       » New Womb-Like Invention for Preterm Infants       » World Asthma Day: Managing and Living with Asthma       » Managing Liver Cancer as a Global Health Problem      
BIOBOARD - AUSTRALIA
Senz Oncology initiates VAL-1000 clinical trial in patients with acute leukemias
Senz Oncology Pty Ltd (Senz) has announced that the first patient has commenced treatment in a Phase I/II clinical evaluation of VAL-1000 in patients with acute leukemias (protocol SO-2012-1). 

The single-arm, open-label clinical trial will be conducted under the guidance of Principal Investigator, Dr. Andrew Wei, Head of Leukemia Services at The Alfred Hospital, Melbourne, Australia.

“We are very pleased to have Dr. Wei as Principal Investigator for the VAL-1000 Phase I/II clinical trial,” said Dr. Ian Nisbet, Executive Director, Senz Oncology. “Dr. Wei's input into the preclinical studies provided new scientific insights and the clinical rationale for VAL-1000 in acute leukaemias”.

The primary objective of the trial is to evaluate the safety and tolerability of VAL-1000 in adult patients with acute leukemias that are unsuitable for treatment with standard chemotherapy treatments. 

The trial will also evaluate secondary objectives including assessing patient related efficacy outcomes, measuring VAL-1000 pharmacokinetics and defining a dose level for testing in subsequent Phase II clinical trials. 

Approximately 900 patients are diagnosed with Acute Myeloid Leukemia (AML) in Australia annually. The majority will relapse, especially those over the age of 60 and with poor risk cytogenetic and molecular characteristics. Patients falling into these categories have very limited treatment options once standard approaches have been exhausted.

According to Dr. Anthony Filippis, Executive Director, Senz Oncology, “The trial will be the first time that VAL-1000 has been tested clinically for the treatment of acute leukaemias; if ultimately shown to be safe and efficacious it could provide a completely new treatment option for patients.”

Click here for the complete issue.

NEWS CRUNCH  
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy